Abstracts tagged "morbidity and mortality and rheumatoid arthritis (RA)"

Abstract Number: 2652 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis and Excess Mortality Associated with Treatments: a Systematic Review and Meta-Analysis
Manon Redondin¹, B Combe², Cécile Gaujoux-Viala³, Jacques Morel⁴ and Cédric Lukas⁵, ¹CHU Lapeyronie, University of Montpellier, France, ²Immuno-Rhumatologie, CHU Lapeyronie, University of Montpellier, France, ³CHU Nîmes, University of Montpellier, France, ⁴Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ⁵Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France
Background/Purpose: Patients with rheumatoid arthritis (RA) have a lower life expectancy than general population. The impact of RA treatments on global mortality is not…
Abstract Number: 3052 • 2016 ACR/ARHP Annual Meeting
Causes of Death for Patients with Rheumatoid Arthritis
Jessica Widdifield¹, Michael Paterson², Anjie Huang³, Bindee Kuriya⁴, Carter Thorne⁵, Janet E. Pope⁶, Claire Bombardier⁷ and Sasha Bernatsky⁸, ¹McGill University, Toronto, ON, Canada, ²Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, ³Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁴Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto and Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Information on causes of death can assist in monitoring health trends and discovering health gaps. Our aim was to determine the primary causes of…
Abstract Number: 1343 • 2015 ACR/ARHP Annual Meeting
Mortality Due to Sepsis in Patients with Rheumatoid Arthritis
Orit Barrett¹, Ella Abramovich², Jacob Dreiher³, Victor Novack⁴ and Mahmoud Abu-Shakra⁵, ¹Department of Medicine D, Soroka Medical Center and Ben-Gurion University, Beersheba, Israel, ²Department of Medicine D, Soroka University Medical Center and Ben-Gurion University, Beersheba, Israel, ³Clalit Health Services, Ben-Gurion University of the Negev, Beer Sheva,,, BeerSheba, Israel, ⁴Clinical Research Center, Soroka Medical Center and Ben-Gurion University, Beersheba, Israel, ⁵Rheumatic Diseases Unit, Soroka Medical Center and Ben-Gurion University, Beer-Sheva, Israel
Background/Purpose: Severe infections contribute significantly to the morbidity and mortality of patients with rheumatoid arthritis. The aim of the study was to identify the characteristics…
Abstract Number: 1534 • 2015 ACR/ARHP Annual Meeting
Temporal Trends and Outcomes of Acute Myocardial Infarction in Rheumatoid Arthritis Hospitalizations
Narender Annapureddy¹, Achint Patel², Rabi Yacoub³, Krishna Pakanati⁴, Shiv Agarwal⁵, Priya Simoes⁶, Shaan Patel³, Sunil Kamat⁷, Alexandre Benjo⁸ and Girish Nadkarni⁹, ¹Rheumatology and Immunology, Vanderbilt University, Nashville, TN, ²Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Gateway Medical Center, Clarksville, TN, ⁵Cardiology, University of Arkansas Medical Sciences, Little Rock, AR, ⁶Internal Medicine, St.Lukes Roosevelt Hospital Center at Mount Sinai, New York, NY, ⁷Critical Care, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India, ⁸Ochsner Clinic Foundation, New Orleans, NY, ⁹Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of cardiac mortality. With better treatment modalities, some studies suggest that infarction (AMI) mortality in RA…
Abstract Number: 1562 • 2015 ACR/ARHP Annual Meeting
Clinical Correlates, Outcomes and Predictors of Episcleritis and Scleritis Associated with Rheumatoid Arthritis
Cristian Caimmi¹, Wendy M. Smith², Cynthia S. Crowson³, Eric L. Matteson⁴ and Ashima Makol⁵, ¹Unit of Rheumatology, Department of Medicine,, University of Verona, Verona, Italy, ²Department of Ophthalmology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
Background/Purpose: Inflammatory ocular disease (IOD) has traditionally been regarded as a severe extra-articular manifestation of rheumatoid arthritis (RA) with high mortality. This study aims to…
Abstract Number: 1999 • 2015 ACR/ARHP Annual Meeting
Improvement in Mortality in RA Compared to the General Population – Closing the Mortality Gap
Diane Lacaille^1,2, Eric C. Sayre³ and Michal Abrahamowicz⁴, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada
Background/Purpose: Increased mortality in RA is believed to be a consequence of inflammation. With improved treatment, mortality would be expected to decrease over time. The…
Abstract Number: 3237 • 2015 ACR/ARHP Annual Meeting
Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA?
Elena Myasoedova¹, Cynthia S. Crowson², Eric L. Matteson³, John M. Davis III⁴, Terry M. Therneau⁵ and Sherine E. Gabriel⁶, ¹Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁵Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁶Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) morbidity and mortality as compared to the general population. Recent prospective studies with limited follow-up…
Abstract Number: 3239 • 2015 ACR/ARHP Annual Meeting
Response to Methotrexate Predicts Mortality in Rheumatoid Arthritis up to 30 Years
Carolin Krause¹, Siegfried Wassenberg², Rolf Rau³, Gertraud Herborn⁴, Juergen Braun⁵ and Dietmar Krause⁶, ¹University Munster, Munster, Germany, ²Rheumaklinik, Themistocles Gluck hospital - Rheumazentrum Ratingen, Ratingen, Germany, ³Expert in Rheumatology, Düsseldorf, Germany, ⁴Evangelisches Fachkrankenhaus Ratingen, Ratingen, Greece, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Dept. for Medical Informatics, Biometry and Epidemiology, Ruhr University, Bochum, Germany
Background/Purpose: Methotrexate (MTX) is considered as the anchor drug for the treatment of patients with rheumatoid arthritis (RA). MTX has been shown to reduce disease…
Abstract Number: 40 • 2015 ACR/ARHP Annual Meeting
Increased Mortality in Indigenous North Americans Persons with Rheumatoid Arthritis Is Partially Explained By Psychiatric and Physical Comorbidity: a Population Based Study
Carol Hitchon¹, Sazzadul Khan², Brenda Elias³, Alan Katz⁴ and Christine A. Peschken⁵, ¹Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, ²Manitoba Centre for Health Policy and Research, University of Manitoba, Winnipeg, MB, Canada, ³Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ⁴Manitoba Centre for Health Policy, University of Manitoba, Winnipeg, MB, Canada, ⁵Arthritis Center, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Rheumatoid Arthritis (RA) is associated with excess mortality. Indigenous North Americans (INA) in our region have high RA prevalence rates and young age at onset yet experience…
Abstract Number: 580 • 2015 ACR/ARHP Annual Meeting
Treatment with Biologic Agents in Rheumatoid Arthritis and Mortality Risk in Clinical Practice
Leticia Leon¹, Luis Rodriguez-Rodriguez¹, Alejandro Gomez-Gomez², Pilar Macarrón², Margarita Blanco², Juan A Jover² and Lydia Abasolo¹, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: It is a well-known fact the decline of life expectancy in Rheumatoid Arthritis (RA) being the increased mortality in these patients a constant concern…
Abstract Number: 2810 • 2014 ACR/ARHP Annual Meeting
Reduced Mortality Risk in Rheumatoid Arthritis: Findings from Two UK Inception Cohorts
Sam Norton¹, Elena Nikiphorou², Lewis Carpenter³, David Walsh^4,5, Patrick Kiely⁶, Josh Dixey⁷ and Adam Young^2,8, ¹Institute of Psychiatry, King's College London, London, United Kingdom, ²School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, ³Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom, ⁴Arthritis Research UK Pain Centre, University of Nottingham, Nottingham, United Kingdom, ⁵Rheumatology, Sherwood Forest Hospitals NHS Foundation Trust, Sutton-in-Ashfield, United Kingdom, ⁶Rheumatology Dept, St. Georges Healthcare NHS Trust, London, United Kingdom, ⁷Rheumatology, New Cross Hospital, Wolverhampton, United Kingdom, ⁸Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom
Background/Purpose Rheumatoid arthritis (RA) is associated with a 20 to 30% increased risk of mortality from all-causes compared to the general population. The aim of…
Abstract Number: 2388 • 2014 ACR/ARHP Annual Meeting
DMARD Use after an Initial Acute MI Is Associated with Reduced Risk of a Recurrent Event and Mortality
Jie Zhang¹, Fenglong Xie², Lang Chen³, Huifeng Yun⁴, Paul M. Muntner⁵, Emily Levitan⁵, Monica Safford⁶, Kenneth G. Saag⁷, Jasvinder A. Singh⁶ and Jeffrey R. Curtis⁶, ¹Ryals Soph Bldg., Rm. 517b, Univ. of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose Previous studies have suggested that disease modifying anti-rheumatic drugs (DMARDs) may reduce cardiovascular risk among patients with rheumatoid arthritis (RA). This analysis examined whether…
Abstract Number: 2116 • 2014 ACR/ARHP Annual Meeting
Hospitalization Rates and Utilization Among Rheumatoid Arthritis Patients: A Population-Based Study from 1987 to 2012
C. John Michet III¹, Katrina Strobova², Sara J. Achenbach³, Cynthia S. Crowson⁴ and Eric L. Matteson⁵, ¹Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, ²Department of Medicine, Charles University, Prague, Czech Republic, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research, Mayo Clinic, Rochester, MN, ⁵Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose Patients with rheumatoid arthritis (RA) experience chronic management issues and are at risk for complex comorbidities. It is unknown, however, to what extent the…
Abstract Number: 2053 • 2014 ACR/ARHP Annual Meeting
Mortality Decreases in Patients with Rheumatoid Arthritis: a 15-Year Prospective Cohort Study
Joëlle van den Hoek^1,2, Hendriek C. Boshuizen³, Leo D. Roorda⁴, Gerard J. Tijhuis⁵, Mike T. Nurmohamed⁵, Trudi van den Bos² and Joost Dekker^6,7, ¹Rehabilitation Research Center, Reade, Rehabilitation | Rheumatology, Amsterdam, Netherlands, ²Social Medicine, Academic Medical Center, Amsterdam, Netherlands, ³National Institute of Public Health and the Environment, Bilthoven, Netherlands, ⁴Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands, ⁷Reade, centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands
Background/Purpose Patients with rheumatoid arthritis (RA) have a higher mortality risk than the general population, with similar patterns over the last decades. However, more recent…
Abstract Number: 1416 • 2014 ACR/ARHP Annual Meeting
Analysis of Cardiac Involvement in Patients with Amyloid a (AA) Amyloidosis Due to Rheumatoidarthritis
Daisuke Kobayashi¹, Satoshi Ito¹, Satoru Kodama¹, Akira Murasawa¹, Ichiei Narita² and Kiyoshi Nakazono¹, ¹Niigata Rheumatic Center, Shibata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Background/Purpose Rheumatoid arthritis (RA) is one of the major causes of amyloid A (AA) amyloidosis. The major organs affected are the kidneys and gastrointestinal (GI)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].